# US 2026/0297172 A1 · Antibodies targeting s100 proteins and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0297172 A1
- Document ID: US20260297172A1
- Status: Published application
- Kind: A1
- Application number: 19/481,206
- Filed: 2024-05-10
- Published: 2026-10-01
- Earliest claimed: 2023-05-22
- Assignees: Albert Einstein College of Medicine
- Applicants: Albert Einstein College of Medicine
- Inventors: Amit Verma; Rongbao Zhao; Srinivas Aluri
- Web page: https://patentgrep.com/patent/US20260297172A1

## CPC

- C07K 16/24: against cytokines, lymphokines or interferons
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 47/6845: {the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon}
- A61K 49/0058: {Antibodies}
- A61K 51/1021: {against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons}
- C07K 17/08: the carrier being a synthetic polymer
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/35: Valency
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This disclosure provides novel neutralizing and potent antibodies targeting S100 proteins, related nucleic acids, related cells, related kits, related compositions, and related methods or uses.

## Claims

### Claim 1

An isolated antibody or antigen-binding fragment thereof that binds specifically to a S100A8/S100A9 hetero-oligomer, wherein the antibody or antigen-binding fragment thereof comprises:
(a) three heavy chain complementarity determining regions (HCDRs) (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO: 1; and three light chain CDRs (LCDR1, LCDR2, and LCDR3) contained within a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 2;
(b) HCDR1, HCDR2, and HCDR3 of a HCVR having the amino acid sequence of SEQ ID NO: 11; and LCDR1, LCDR2, and LCDR3 of a LCVR having the amino acid sequence of SEQ ID NO: 12;
(c) HCDR1, HCDR2, and HCDR3 of a HCVR having the amino acid sequence of SEQ ID NO: 21; and LCDR1, LCDR2, and LCDR3 of a LCVR having the amino acid sequence of SEQ ID NO: 22;
(d) HCDR1, HCDR2, and HCDR3 of a HCVR having the amino acid sequence of SEQ ID NO: 31; and LCDR1, LCDR2, and LCDR3 of a LCVR having the amino acid sequence of SEQ ID NO: 32;
(e) HCDR1, HCDR2, and HCDR3 of a HCVR having the amino acid sequence of SEQ ID NO: 41; and LCDR1, LCDR2, and LCDR3 of a LCVR having the amino acid sequence of SEQ ID NO: 42;
(f) HCDR1, HCDR2, and HCDR3 of a HCVR having the amino acid sequence of SEQ ID NO: 51; and LCDR1, LCDR2, and LCDR3 of a LCVR having the amino acid sequence of SEQ ID NO: 52;
(g) HCDR1, HCDR2, and HCDR3 of a HCVR having the amino acid sequence of SEQ ID NO: 61; and LCDR1, LCDR2, and LCDR3 of a LCVR having the amino acid sequence of SEQ ID NO: 62; or
(h) HCDR1, HCDR2, and HCDR3 of a HCVR having the amino acid sequence of SEQ ID NO: 71; and LCDR1, LCDR2, and LCDR3 of a LCVR having the amino acid sequence of SEQ ID NO: 72.

### Claim 2 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 sequences respectively set forth in a CDR sequence set selected from the group consisting of SEQ ID NOs: 3-8, 13-18, 23-28, 33-38, 43-48, 53-58, 63-68, and 73-78.

### Claim 3 (depends on 1)

The antibody or antigen-binding fragment thereof of, claim 1 comprising:
(a) a HCVR comprising an amino acid sequence with at least 75% identity to the amino acid sequence of SEQ ID NO: 1 or comprising the amino acid sequence of SEQ ID NO: 1; and a LCVR comprising an amino acid sequence with at least 75% identity to the amino acid sequence of SEQ ID NO: 2 or comprising the amino acid sequence of SEQ ID NO: 2;
(b) a HCVR comprising an amino acid sequence with at least 75% identity to the amino acid sequence of SEQ ID NO: 11 or comprising the amino acid sequence of SEQ ID NO: 11; and a LCVR comprising an amino acid sequence with at least 75% identity to the amino acid sequence of SEQ ID NO: 12 or comprising the amino acid sequence of SEQ ID NO: 12;
(c) a HCVR comprising an amino acid sequence with at least 75% identity to the amino acid sequence of SEQ ID NO: 21 or comprising the amino acid sequence of SEQ ID NO: 21; and a LCVR comprising an amino acid sequence with at least 75% identity to the amino acid sequence of SEQ ID NO: 22 or comprising the amino acid sequence of SEQ ID NO: 22′
(d) a HCVR comprising an amino acid sequence with at least 75% identity to the amino acid sequence of SEQ ID NO: 31 or comprising the amino acid sequence of SEQ ID NO: 31; and a LCVR comprising an amino acid sequence with at least 75% identity to the amino acid sequence of SEQ ID NO: 32 or comprising the amino acid sequence of SEQ ID NO: 32;
(e) a HCVR comprising an amino acid sequence with at least 75% identity to the amino acid sequence of SEQ ID NO: 41 or comprising the amino acid sequence of SEQ ID NO: 41; and a LCVR comprising an amino acid sequence with at least 75% identity to the amino acid sequence of SEQ ID NO: 42 or comprising the amino acid sequence of SEQ ID NO: 42;
(f) a HCVR comprising an amino acid sequence with at least 75% identity to the amino acid sequence of SEQ ID NO: 51 or comprising the amino acid sequence of SEQ ID NO: 51; and a LCVR comprising an amino acid sequence with at least 75% identity to the amino acid sequence of SEQ ID NO: 52 or comprising the amino acid sequence of SEQ ID NO: 52;
(g) a HCVR comprising an amino acid sequence with at least 75% identity to the amino acid sequence of SEQ ID NO: 61 or comprising the amino acid sequence of SEQ ID NO: 61; and a LCVR comprising an amino acid sequence with at least 75% identity to the amino acid sequence of SEQ ID NO: 62 or comprising the amino acid sequence of SEQ ID NO: 62; or
(h) a HCVR comprising an amino acid sequence with at least 75% identity to the amino acid sequence of SEQ ID NO: 71 or comprising the amino acid sequence of SEQ ID NO: 71; and a LCVR comprising an amino acid sequence with at least 75% identity to the amino acid sequence of SEQ ID NO: 72 or comprising the amino acid sequence of SEQ ID NO: 72.

### Claim 4 (depends on 1)

The antibody or antigen-binding fragment thereof of, claim 1, comprising a HCVR and a LCVR that comprise a HCVR and LCVR amino acid sequence pair of SEQ ID NOs: 1-2, 11-12, 21-22, 31-32, 41-42, 51-52, 61-62, or 71-72.

### Claim 5 (depends on 1)

The antibody or antigen-binding fragment thereof of, claim 1, comprising a heavy chain (HC) and a light chain (LC) that comprise a HC and LC amino acid sequence pair of SEQ ID NOs: 9-10, 19-20, 29-30, 39-40, 49-50, 59-60, 69-70, or 79-80.

### Claim 6 (depends on 1)

The antibody or antigen-binding fragment thereof of, claim 1, wherein the antibody or antigen-binding fragment thereof is a 6C8 antibody, a 8H6 antibody, or a 14G9 antibody.

### Claim 7 (depends on 1)

The antibody or antigen-binding fragment thereof of, claim 1, wherein the S100A8/S100A9 hetero-oligomer comprises a S100A8/S100A9 heterodimer.

### Claim 8 (depends on 1)

The antibody or antigen-binding fragment thereof of, claim 1, wherein the S100A8 protein is a human S100A8 protein and the S100A9 protein is a human S100A9 protein.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The antibody or antigen-binding fragment thereof of, claim 1, wherein the antibody is a monoclonal or polyclonal antibody.

### Claim 11 (depends on 1)

The antibody or antigen-binding fragment thereof of, claim 1, wherein the antibody is a bivalent or bispecific antibody.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The antibody or antigen-binding fragment thereof of, claim 1, wherein the antibody is a chimeric antibody, a humanized antibody, or a humanized monoclonal antibody.

### Claim 14 (depends on 1)

The antibody or antigen-binding fragment thereof of, claim 1, wherein the antibody or antigen-binding fragment thereof comprises a single-chain antibody, Fab or Fab2 fragment.

### Claim 15 (depends on 1)

The antibody or the antigen-binding fragment thereof of, claim 1, wherein the antibody or antigen-binding fragment thereof comprises a variant Fc constant region.

### Claim 16 (depends on 1)

The antibody or antigen-binding fragment thereof of, claim 1, wherein the antibody or antigen-binding fragment thereof is detectably labeled or conjugated to a toxin, a therapeutic agent, a polymer, a receptor, an enzyme, or a receptor ligand, preferably wherein the polymer is polyethylene glycol (PEG).

### Claim 17 (depends on 1)

A nucleic acid molecule encoding a polypeptide chain of the antibody or antigen-binding fragment thereof of claim 1.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21 (depends on 1)

A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 1; and optionally a pharmaceutically acceptable carrier or excipient.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24 (depends on 1)

A method of treating a disease or disorder in a subject in need thereof, comprising administering to the subject the antibody or antigen-binding fragment thereof of, claim 1.

### Claim 25 (depends on 24)

The method of claim 24, wherein the disease or disorder comprises leukemia, myelodysplastic syndromes (MDS), or an inflammatory and autoimmune disease.

### Claim 26 (depends on 25)

The method of claim 25, wherein the leukemia is acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), or chronic myelomonocytic leukemia (CMML).

### Claim 27 (depends on 24)

The method of claim 24, wherein the inflammatory and autoimmune disease is non-neoplastic inflammation

### Claim 28 (depends on 24)

The method of claim 24, wherein further comprising administering to the subject an additional therapeutic agent or therapy.

### Claim 29 (depends on 28)

The method of claim 28, wherein the additional therapeutic agent or therapy comprises at least one of daunorubicin, doxorubicin, and cytarabine.

### Claim 30 (depends on 28)

The method of claim 28, wherein the antibody or antigen-binding fragment thereof is administered before, after, or concurrently with the additional therapeutic agent or therapy.

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45

(canceled)

### Claim 46

(canceled)
